EDURANT
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $453,072 | 7 | 0 |
| 2023 | $711,073 | 4 | 1 |
| 2022 | $2.3M | 10 | 0 |
| 2021 | $113.80 | 4 | 3 |
| 2020 | $17,676 | 16 | 16 |
| 2019 | $137,865 | 144 | 25 |
| 2018 | $357,278 | 140 | 23 |
| 2017 | $101,405 | 16 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 32 | 96.8% |
| Consulting Fee | $102,000 | 36 | 2.5% |
| Travel and Lodging | $21,747 | 95 | 0.5% |
| Food and Beverage | $5,473 | 178 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension | Janssen Research & Development, LLC | $3.4M | 0 |
| A Phase 1, Open-label, Randomized, Parallel-group Study in Healthy Subjects to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension | Janssen Research & Development, LLC | $305,726 | 0 |
| A Phase IV 96 Week, Open Label, Pilot Study of PREZISTA Boosted by Cobicistat in Combination with EDURANT to Treat HIV+ Naive Subjects (PREZENT) | Janssen Research & Development, LLC | $179,412 | 0 |
Top Doctors Receiving Payments for EDURANT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $3.9M | 42 |
| , MD | Internal Medicine | New York, NY | $10,585 | 22 |
| , M.D | Infectious Disease | Atlanta, GA | $10,511 | 21 |
| , M.D | Internal Medicine | Seattle, WA | $10,267 | 17 |
| , M.D | Internal Medicine | Chicago, IL | $9,397 | 17 |
| , MD | Internal Medicine | West Hollywood, CA | $8,936 | 21 |
| Princy Kumar | Infectious Disease | Washington, DC | $8,611 | 27 |
| , M.D | Internal Medicine | New York, NY | $8,520 | 19 |
| , MD | Infectious Disease | Altamonte Springs, FL | $8,402 | 21 |
| , MD | Infectious Disease | Chicago, IL | $7,738 | 17 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $6,635 | 13 |
| , MD | Infectious Disease | Fort Pierce, FL | $6,299 | 11 |
| , MD | Infectious Disease | Newark, NJ | $6,125 | 10 |
| , MD | Infectious Disease | Chapel Hill, NC | $4,341 | 10 |
| , M.D | Internal Medicine | Cincinnati, OH | $4,135 | 9 |
| , MD | Infectious Disease | Flushing, NY | $4,067 | 9 |
| , M.D | Infectious Disease | Pinehurst, NC | $3,938 | 8 |
| , DO | Family Medicine | Columbus, OH | $1,840 | 2 |
| , M.D | Infectious Disease | Orlando, FL | $1,750 | 1 |
| , MD | Infectious Disease | Philadelphia, PA | $1,750 | 1 |
| , MD | Family Medicine | New York, NY | $155.67 | 6 |
| , M.D | Internal Medicine | Bronx, NY | $96.11 | 1 |
| , MD | Internal Medicine | New York, NY | $77.89 | 1 |
| , MD | Infectious Disease | Jacksonville, FL | $66.17 | 1 |
| , M.D | Clinical Pharmacology | Baltimore, MD | $47.52 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.0M
- Total Doctors 55
- Transactions 341
About EDURANT
EDURANT is a drug associated with $4.0M in payments to 55 healthcare providers, recorded across 341 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $453,072 was paid across 7 transactions to 0 doctors.
The most common payment nature for EDURANT is "Unspecified" ($3.9M, 96.8% of total).
EDURANT is associated with 3 research studies, including "A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension" ($3.4M).